Lauri Jouhi1, Jaana Hagström, Timo Atula, Antti Mäkitie. 1. aDepartment of Otorhinolaryngology - Head and Neck Surgery bDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland cDivision of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Abstract
PURPOSE OF REVIEW: In head and neck cancer management, immunoexpression of protein p16 is widely used as a surrogate marker for human papillomavirus (HPV) positivity due to challenges of direct HPV testing. Previously p16 has been reported to have good sensitivity but only moderate specificity in HPV-status determination. The aim of this review is to evaluate the existing information on sensitivity and specificity of p16 immunohistochemistry (IHC) in HPV-status determination among the recent studies. RECENT FINDINGS: We searched the time period from October 2014 to April 2016 and included 28 studies (a total of 31 analyses), which reported both p16 and HPV status in their series. The sensitivity of p16 in HPV determination ranged between 28.2 and 100.0%. The mean and median sensitivities were 90.5 and 95.4%, respectively. The specificity ranged between 31.1 and 100.0%. The mean and median specificities were 83.3 and 87.3%, respectively. SUMMARY: Our review presents current information on the feasibility of p16 IHC in HPV status determination, which is in line with previous studies. Patients with HPV-positive tumors can be identified with p16 IHC, but a risk for misclassification of HPV-negative tumors as HPV positive exists. This fact has to be taken into consideration if HPV status will influence treatment planning.
PURPOSE OF REVIEW: In head and neck cancer management, immunoexpression of protein p16 is widely used as a surrogate marker for human papillomavirus (HPV) positivity due to challenges of direct HPV testing. Previously p16 has been reported to have good sensitivity but only moderate specificity in HPV-status determination. The aim of this review is to evaluate the existing information on sensitivity and specificity of p16 immunohistochemistry (IHC) in HPV-status determination among the recent studies. RECENT FINDINGS: We searched the time period from October 2014 to April 2016 and included 28 studies (a total of 31 analyses), which reported both p16 and HPV status in their series. The sensitivity of p16 in HPV determination ranged between 28.2 and 100.0%. The mean and median sensitivities were 90.5 and 95.4%, respectively. The specificity ranged between 31.1 and 100.0%. The mean and median specificities were 83.3 and 87.3%, respectively. SUMMARY: Our review presents current information on the feasibility of p16 IHC in HPV status determination, which is in line with previous studies. Patients with HPV-positive tumors can be identified with p16 IHC, but a risk for misclassification of HPV-negative tumors as HPV positive exists. This fact has to be taken into consideration if HPV status will influence treatment planning.
Authors: Inmaculada Ribera-Cortada; José Guerrero-Pineda; Isabel Trias; Luis Veloza; Adriana Garcia; Lorena Marimon; Sherley Diaz-Mercedes; José Ramon Alamo; Maria Teresa Rodrigo-Calvo; Naiara Vega; Ricardo López Del Campo; Rafael Parra-Medina; Tarek Ajami; Antonio Martínez; Oscar Reig; Maria J Ribal; Juan Manuel Corral-Molina; Pedro Jares; Jaume Ordi; Natalia Rakislova Journal: Int J Mol Sci Date: 2021-12-27 Impact factor: 5.923
Authors: Amy Dickinson; Mayank Saraswat; Stina Syrjänen; Tiialotta Tohmola; Robert Silén; Reija Randén-Brady; Timo Carpén; Jaana Hagström; Caj Haglund; Petri Mattila; Antti Mäkitie; Sakari Joenväärä; Suvi Silén Journal: PLoS One Date: 2020-06-15 Impact factor: 3.240